A Phase i study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 1, 2013, Pages 93-101

  Plummer, Ruth ^a   Madi, Ayman ^a   Jeffels, Melinda ^a   Richly, Heike ^b   Nokay, Bahar ^b   Rubin, Stephen ^c   Ball, Howard A ^c,d   Weller, Steve ^c   Botbyl, Jeffrey ^e   Gibson, Diana M ^c   Scheulen, Max E ^b  

^a Northern Centre for Cancer Care   (United Kingdom)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c GLAXOSMITHKLINE   (United States)

^d Astellas   (United States)

^e Provonix ^*  (United States)

Author keywords

Anti angiogenesis; Combination therapy; Gemcitabine; Melanoma; Pazopanib; Pharmacokinetics; Phase I; Solid tumors

Indexed keywords

GEMCITABINE; PAZOPANIB;

ADULT; ADVANCED CANCER; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; EPISTAXIS; ESOPHAGUS CANCER; FATIGUE; FEMALE; HAIR COLOR; HEMATOMA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERINE CERVIX CANCER;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872287977     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1982-z     Document Type: Article

References (21)

1. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061-1068
2. van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879-1886
3. Altorki N, Lane ME, Bauer T et al (2010) Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 28:3131-3137
4. Bible KC, Suman VJ, Molina JR et al (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11:962-972
5. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119:32-37
6. Sleijfer S, Papai Z, Le Cesne A et al (2007) Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043 (abstr 10031). J Clin Oncol 18S:552s
7. Monk BJ, Mas Lopez L, Zarba JJ et al (2010) Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:3562-3569
8. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
9. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13:2731-2736
10. Lund B, Hansen OP, Neijt JP, Theilade K, Hansen M (1995) Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs 6:61-62
11. Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130
12. Maki RG, Wathen JK, Patel SR et al (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25:2755-2763
13. Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498
14. Martin C, Pollera CF (1996) Gemcitabine: safety profile unaffected by starting dose. Int J Clin Pharmacol Res 16:9-18
15. Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J (2011) Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 9:CD007930
16. Ulahannan SV, Brahmer JR (2011) Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 29:325-337
17. Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S (2009) Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 3:CD005392
18. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
19. Goh BC, Reddy NJ, Dandamudi UB et al (2010) An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 88:652-659
20. Eli Lilly and Company (2012) Gemzar (gemcitabine for injection) powder prescribing information. Revised February 2011 [cited January 5, 2012]. Available from: http://pi.lilly.com/us/gemzar.pdf
21. Jiang X, Galettis P, Links M, Mitchell PL, McLachlan AJ (2008) Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. Br J Clin Pharmacol 65:326-333